Tissue factor pathway inhibitor anticoagulant activity: risk for venous thrombosis and effect of hormonal state
Open Access
- 29 November 2005
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 132 (3), 333-338
- https://doi.org/10.1111/j.1365-2141.2005.05876.x
Abstract
Full‐length tissue factor pathway inhibitor (TFPI) is assumed to be biologically more important than truncated TFPI because of its stronger anticoagulant effect in the diluted prothrombin time (dPT) assay. We have developed a dPT‐based assay for TFPI anticoagulant activity. Here, we report the effect of hormonal state on TFPI anticoagulant activity and whether TFPI anticoagulant activity assesses the risk for deep‐vein thrombosis (DVT) better than conventional TFPI assays. We undertook a case‐control study of 474 patients with DVT and 474 controls and compared the odds ratio (OR) for DVT for those with low TFPI anticoagulant activity with the ORs obtained for TFPI free and total antigen, and TFPI chromogenic substrate activity. Hormonal state affected clot time in dPT, but this effect was ameliorated by anti‐TFPI antibodies. Low TFPI anticoagulant activity gave an OR of 1·5 (0·97–2·1) for DVT, similar to the ORs obtained with conventional TFPI assays, ranging from 1·2 to 1·4. Individuals low in both the activity assays obtained an OR of 5·9 (1·7–20). We concluded that the effect of hormonal state on dPT was mediated through TFPI, and a dPT‐based assay of TFPI anticoagulant activity did not assess the risk for DVT better than conventional TFPI assays.Keywords
This publication has 33 references indexed in Scilit:
- Determinants of the APTT‐ and ETP‐based APC sensitivity testsJournal of Thrombosis and Haemostasis, 2005
- The quest for the Holy Grail of tissue factor pathway inhibitor deficiency has just begunJournal of Thrombosis and Haemostasis, 2005
- A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI)Journal of Thrombosis and Haemostasis, 2005
- Endothelial Cell Markers and the Risk of Coronary Heart DiseaseCirculation, 2004
- Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosisBlood, 2003
- Effect of Cholesterol Lowering on Intravascular Pools of TFPI and Its Anticoagulant Potential in Type II HyperlipoproteinemiaArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994
- Antithrombotic Properties of a Truncated Recombinant Tissue Factor Pathway Inhibitor in an Experimental Venous Thrombosis ModelPathophysiology of Haemostasis and Thrombosis, 1993
- The present status of tissue factor pathway inhibitorBlood Coagulation & Fibrinolysis, 1992
- Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patientsBlood Coagulation & Fibrinolysis, 1991